Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 10/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27737992 | 0.88 | ALDH1A1 (0.50) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL3917277 | 0.87 | ALDH1A1 (0.48) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL3917977 | 0.83 | KEAP1 (0.50) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL646518 | 0.83 | ALDH1A1 (0.54) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL27737966 | 0.82 | ALDH1A1 (0.47) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL4956387 | 0.78 | ALDH1A1 (0.53) | ALDH1A1PTPN1PTPN6PTPN2PTPN11 | |
| SCHEMBL2892656 | 0.77 | ALDH1A1 (0.51) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL2892950 | 0.76 | ALDH1A1 (0.48) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 | |
| SCHEMBL629539 | 0.76 | MAOB (0.45) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL3922237 | 0.76 | ALDH1A1 (0.46) | ALDH1A1PTPN1PTPN6PTPN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | ALDH1A1 2621/4885PTPN1 21/4885PTPN6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.